User:Mr. Ibrahem/Streptozotocin

Mr. Ibrahem/Streptozotocin
Clinical data
Trade namesZanosar
AHFS/Drugs.comMonograph
MedlinePlusa684053
Routes of
administration
Intravenous
Drug classAlkylating agent[1]
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability17–25% (100% if IV)
MetabolismLiver, kidney
Elimination half-life35–40 minutes
Identifiers
  • 2-Deoxy-2-({[methyl(nitroso)amino]carbonyl}amino)-β-D-glucopyranose
Chemical and physical data
FormulaC8H15N3O7
Molar mass265.222 g·mol−1
3D model (JSmol)
  • CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O)N=O
  • InChI=1S/C8H15N3O7/c1-11(10-17)8(16)9-4-6(14)5(13)3(2-12)18-7(4)15/h3-7,12-15H,2H2,1H3,(H,9,16)/t3-,4-,5-,6-,7+/m1/s1 checkY
  • Key:ZSJLQEPLLKMAKR-GKHCUFPYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Streptozotocin, also known as streptozocin (STZ), is a medication used for treating certain islet cell cancer of the pancreas, carcinoid tumor, and pancreatic adenocarcinoma.[1] It is given by injection into a vein.[1]

Common side effects include nausea, kidney problems, and bone marrow suppression.[1] Other side effects may include liver problems, confusion, and pain at the site of injection.[1] Use during pregnancy may harm the baby.[1] It is a alkylating agent.[1]

Streptozotocin was approved for medical use in the United States in 1982.[1] In the United Kingdom it cost the NHS about £570 per 1 gram as of 2021.[2] This amount in the United States costs about 370 USD.[3] It is sold under the brand name Zanosar among others.[1]

References edit

  1. ^ a b c d e f g h i j k "Streptozocin Monograph for Professionals". Drugs.com. Archived from the original on 7 September 2015. Retrieved 14 October 2021.
  2. ^ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 949. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
  3. ^ "Zanosar Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 15 October 2021.